Close Menu

NEW YORK (GenomeWeb) – Roche said today that the US Food and Drug Administration has granted premarket approval for expanded use of its Cobas EGFR Mutation Test v2 as a companion diagnostic test with AstraZeneca's Tagrisso (osimertinib) for non-small cell lung cancer patients.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.